In April 2022, the United Kingdom's public health authorities issued an alert that would eventually reach every major pediatric center on the planet. Ten children in central Scotland had been admitted to hospitals with severe hepatitis — liver inflammation so aggressive that it could not be explained by any of the five known hepatitis viruses. None of the standard tests came back positive. Within weeks, similar cases surfaced in the United States, Spain, Israel, Japan, and more than thirty other countries. Some children turned yellow overnight. Some needed intensive care. Some needed new livers entirely.

By the time the World Health Organization closed its investigation in mid-2023, at least 1,010 probable cases had been reported across 35 countries. Roughly 5 percent of those children required liver transplantation. At least 22 died. The cause remained, and to some extent still remains, a subject of scientific debate — though the leading hypothesis now points to an obscure virus that most people have never heard of.

The 2022 outbreak was frightening. But it also exposed a broader gap: most parents know very little about hepatitis in general, about the different viruses that cause it, about which ones are preventable with vaccines, or about the warning signs that a child's liver is in trouble. Hepatitis is not one disease. It is at least five distinct viral infections, each with its own transmission route, severity profile, and treatment landscape — plus a range of non-viral causes that can be equally dangerous. Some forms are mild and self-limiting. Others can silently destroy a child's liver over years. Two are preventable with routine childhood vaccines that have been available for decades.

This article covers all of it: the five hepatitis viruses and what each means for children, the 2022 mystery outbreak and what scientists ultimately concluded, the vaccines that prevent the two most common childhood forms, the jaundice warning signs every parent should recognize, and the basics of keeping a child's liver healthy.

The Liver: Why It Matters So Much in Children

Before understanding hepatitis, it helps to understand what the liver does — because the organ's importance is routinely underestimated. The liver is the largest solid organ in the body, and in children it is proportionally even larger relative to body size than in adults. It performs over 500 distinct functions, including filtering toxins from the blood, producing bile for fat digestion, manufacturing proteins essential for blood clotting, storing glycogen for energy regulation, metabolizing medications, and playing a central role in immune function.

A child's liver is also more metabolically active than an adult's. Children are growing, building new tissue, and processing nutrients at rates that demand heavy hepatic involvement. This means that when a child's liver is inflamed or damaged, the consequences can cascade rapidly — affecting growth, nutrition, immune defense, and energy levels simultaneously.

The word "hepatitis" simply means inflammation of the liver. It can be caused by viruses (the most common cause in children), autoimmune reactions, metabolic diseases, toxins, or medications. When clinicians refer to hepatitis A, B, C, D, or E, they are referring specifically to the five identified viruses that preferentially target liver cells. But hepatitis as a condition — liver inflammation — has a much broader set of causes, which is exactly what made the 2022 outbreak so alarming: the inflammation was severe, but none of the usual viral suspects were responsible.

Hepatitis A: The Traveler's Virus

Hepatitis A virus (HAV) is the most common cause of acute viral hepatitis in children worldwide. It spreads through the fecal-oral route — contaminated water, food (particularly raw or undercooked shellfish), or direct contact with an infected person. In countries with inadequate sanitation infrastructure, the majority of children are exposed before age 10. In high-income countries, exposure is far less common, which paradoxically creates a vulnerability: when cases do occur in populations without prior immunity, they can be more symptomatic.

In children under six years old, hepatitis A is usually mild or even asymptomatic — roughly 70 percent of infected young children show no symptoms at all. When symptoms do appear, they typically include fatigue, nausea, abdominal pain, loss of appetite, and occasionally jaundice (yellowing of the skin and eyes). The illness is almost always self-limiting, resolving within two to six weeks without any specific treatment. Chronic infection does not occur — once the immune system clears the virus, the person has lifelong immunity.

However, hepatitis A is not always benign. In rare cases — estimated at roughly 0.5 to 1 percent of symptomatic infections — HAV can cause fulminant hepatic failure, a rapidly progressive and life-threatening condition. The risk of severe outcomes increases with age and with pre-existing liver disease. A 2019 review in The Lancet estimated that hepatitis A caused approximately 7,134 deaths globally in 2016, with children in low-income settings disproportionately affected.

The hepatitis A vaccine, first licensed in 1995, is one of the most effective vaccines ever developed. Two doses provide essentially lifelong protection, with seroconversion rates exceeding 95 percent after the first dose and approaching 100 percent after the second. The WHO recommends routine childhood hepatitis A vaccination in countries with intermediate endemicity, and the CDC recommends it for all children in the United States at age 12 to 23 months. Despite this, global coverage remains uneven — a 2021 analysis in Vaccine found that only 34 countries had incorporated hepatitis A vaccination into their routine childhood immunization schedules.

Hepatitis B: The Silent Chronic Threat

Hepatitis B virus (HBV) is a fundamentally different problem from hepatitis A. While HAV is typically an acute, self-resolving illness, HBV can establish chronic infection — and the younger the child at the time of infection, the higher the risk of chronicity. This inverse relationship between age and chronic risk is one of the most important facts in pediatric hepatology.

When adults are infected with HBV, approximately 95 percent clear the virus spontaneously and develop protective immunity. But when newborns are infected — typically through vertical transmission from an HBV-positive mother during birth — the chronic infection rate is approximately 90 percent. For children infected between ages one and five, the chronic rate is roughly 25 to 50 percent. This dramatic age dependence occurs because the immature immune system of a neonate is more likely to tolerate the virus rather than mount an aggressive immune response against it.

Chronic hepatitis B is often called the "silent" infection because it can persist for decades without causing symptoms. During this time, the virus slowly damages liver tissue, promoting fibrosis (scarring) and increasing the risk of cirrhosis and hepatocellular carcinoma (liver cancer). The WHO estimated in 2024 that approximately 254 million people worldwide are living with chronic HBV infection, and that the virus causes approximately 1.1 million deaths annually — primarily from cirrhosis and liver cancer that develop decades after initial infection.

For children, the implications are stark. A child who acquires chronic HBV at birth faces a 15 to 25 percent lifetime risk of dying from HBV-related liver disease if untreated. This is why the hepatitis B vaccine, first available in 1982, is now considered one of the most important vaccines in the global immunization arsenal. The WHO recommends a birth dose within 24 hours of delivery, followed by two or three additional doses in the first six months of life. In countries with high HBV prevalence, this strategy has been transformative. Taiwan, which implemented universal infant hepatitis B vaccination in 1984, documented an 80 percent reduction in childhood hepatocellular carcinoma within 20 years — the first demonstration that a vaccine could prevent a human cancer.

A 2020 meta-analysis in The Lancet Infectious Diseases estimated that global coverage with the third dose of hepatitis B vaccine reached 85 percent in 2019, but birth dose coverage remained much lower at approximately 43 percent — leaving a critical gap in protection against mother-to-child transmission.

Hepatitis C: Rare in Children, Growing in Importance

Hepatitis C virus (HCV) is primarily a disease of adults, transmitted through blood-to-blood contact — historically through contaminated blood transfusions (before screening was implemented in the 1990s) and currently through injection drug use. However, HCV in children is not negligible, and the primary route of pediatric infection is vertical transmission from mother to child during pregnancy or delivery, occurring in approximately 5 to 6 percent of births to HCV-positive mothers.

The epidemiology has shifted in recent years. The opioid epidemic in the United States and other countries has driven a sharp increase in HCV prevalence among women of reproductive age, which in turn has increased the number of HCV-exposed infants. A 2018 study in Hepatology reported that the rate of HCV infection among women giving birth in the United States more than doubled between 2009 and 2014.

Unlike hepatitis B, there is no vaccine for hepatitis C. However, the treatment landscape has been revolutionized by direct-acting antivirals (DAAs), which can cure chronic HCV infection in over 95 percent of cases with 8 to 12 weeks of oral medication. In 2017, the FDA approved sofosbuvir/ledipasvir for children as young as 12, and in 2020 approval was extended to children aged 3 and older. A 2020 clinical trial in the New England Journal of Medicine demonstrated cure rates exceeding 97 percent in children aged 3 to 17 treated with sofosbuvir/velpatasvir.

The challenge is screening. The CDC updated its recommendations in 2020 to include universal HCV screening for all pregnant women during each pregnancy, but implementation remains inconsistent. Many HCV-exposed children are never tested, and since pediatric chronic HCV is usually asymptomatic for years, the infection can go undetected until significant liver damage has occurred.

Hepatitis D and E: Less Common but Not Irrelevant

Hepatitis D

Hepatitis D virus (HDV) is unique among human pathogens: it is a defective virus that cannot replicate without the presence of hepatitis B. HDV requires the HBV surface antigen to form its viral envelope, meaning that hepatitis D infection can only occur in people who are already infected with hepatitis B — either as a co-infection (both acquired simultaneously) or as a superinfection (HDV acquired by someone with existing chronic HBV).

Superinfection is the more dangerous scenario. When HDV is added to chronic HBV, the rate of progression to cirrhosis is significantly accelerated — a 2020 systematic review in the Journal of Hepatology found that HDV superinfection tripled the risk of cirrhosis compared to HBV monoinfection. Globally, an estimated 12 to 72 million people have HDV infection, though precise numbers are difficult to establish because testing is inconsistent.

For children, the hepatitis B vaccine is also the hepatitis D vaccine. By preventing HBV infection, vaccination eliminates the possibility of HDV infection entirely. This is one of the strongest arguments for universal hepatitis B vaccination starting at birth.

Hepatitis E

Hepatitis E virus (HEV) is transmitted through the fecal-oral route, similar to hepatitis A, and is the most common cause of acute viral hepatitis globally. In most cases, it causes a self-limiting illness similar to hepatitis A. However, hepatitis E is uniquely dangerous during pregnancy, particularly in the third trimester, when it can cause fulminant liver failure with mortality rates of 20 to 25 percent — a figure that is astonishingly high for a viral hepatitis.

In children, hepatitis E generally behaves like hepatitis A: acute, self-limiting, and rarely severe. However, cases of prolonged and chronic HEV infection have been documented in immunocompromised children, particularly organ transplant recipients on immunosuppressive therapy. A vaccine against HEV (Hecolin) was licensed in China in 2011, but it is not yet available globally and is not included in any routine childhood immunization schedule outside China.

The 2022 Mystery Outbreak: What Actually Happened

The cluster of severe hepatitis cases in previously healthy children that emerged in spring 2022 was alarming precisely because it defied the standard diagnostic categories. These children — mostly under the age of five — presented with acute hepatitis severe enough to require hospitalization, yet tested negative for hepatitis A, B, C, D, and E. The cases were also not explained by autoimmune hepatitis, metabolic liver disease, or toxic exposure.

The UK Health Security Agency (UKHSA) issued the first formal alert on April 5, 2022. By April 15, the WHO had classified the situation as an event of international concern. By July, reports had been filed from 35 countries across five continents.

The clinical picture was distinctive. Children typically presented with gastrointestinal symptoms — vomiting, diarrhea, abdominal pain — followed within days by the onset of jaundice. Liver enzyme levels were dramatically elevated, often ten to twenty times the upper limit of normal. In the most severe cases, liver function deteriorated rapidly enough to require emergency transplantation.

Several hypotheses were investigated simultaneously. Early attention focused on adenovirus type 41 (HAdV-41), a common cause of pediatric gastroenteritis that had not previously been associated with severe hepatitis. A 2022 investigation in the New England Journal of Medicine by the UKHSA found that 75 percent of the UK cases tested positive for adenovirus, with HAdV-41 identified in the majority of typed samples. However, adenovirus was also detected at high rates in control children who did not have hepatitis, complicating the causal interpretation.

A competing and ultimately more compelling hypothesis emerged from molecular analyses. Two studies published in Nature in March 2023 identified adeno-associated virus 2 (AAV2) — a small, typically harmless dependoparvovirus — in liver tissue from affected children at significantly higher rates than in controls. AAV2, like hepatitis D virus, normally requires a helper virus (usually an adenovirus or herpesvirus) to replicate. The proposed mechanism was that co-infection with a common adenovirus (HAdV-41 or others) and AAV2, in genetically susceptible children carrying a specific HLA class II allele (DRB1*04:01), triggered an aberrant immune response that attacked the liver.

A study published in Nature by researchers at the University of Glasgow and UCL analyzed 32 affected children and found AAV2 in the blood of 26 of them (81 percent), compared to just 5 of 113 hospital controls (4 percent). The children with the most severe hepatitis had the highest AAV2 viral loads. Critically, adenovirus was present in both cases and controls, but the combination of adenovirus plus high AAV2 load was strongly associated with liver disease.

The timing of the outbreak also mattered. Many researchers noted that the affected children were born during or just after COVID-19 pandemic lockdowns, meaning they had missed the typical early-childhood exposure to common viruses. This "immunity gap" hypothesis suggested that when these children finally encountered adenoviruses and AAV2 simultaneously after social restrictions eased, their naive immune systems responded in an atypically aggressive manner. A 2023 modeling study in Eurosurveillance supported this interpretation, showing that the age distribution of cases aligned with a cohort of children who would have had minimal viral exposure during their first one to two years of life.

By mid-2023, new cases had declined to background rates, and the WHO downgraded its assessment. The outbreak appeared to be a transient consequence of unusual epidemiological conditions rather than the emergence of a new persistent threat. But it left behind important lessons about the fragility of liver health in young children and the complexity of viral interactions.

Jaundice Warning Signs: What Parents Need to Watch For

Jaundice — the yellowing of the skin and the whites of the eyes — is the most visible sign of liver distress in children. It occurs when bilirubin, a yellow pigment produced by the normal breakdown of red blood cells, accumulates in the blood because the liver cannot process and excrete it efficiently.

Newborn jaundice is extremely common (affecting roughly 60 percent of full-term and 80 percent of preterm infants) and is usually physiological — a result of the immature liver's limited capacity to process the bilirubin load from the rapid turnover of fetal red blood cells. This typically resolves within one to two weeks. However, jaundice that persists beyond 14 days, appears within the first 24 hours of life, or is accompanied by pale (chalky white) stools and dark urine requires urgent evaluation, as it may indicate biliary atresia or another serious hepatobiliary condition.

In older children, jaundice is never normal and always warrants medical evaluation. The key warning signs of hepatitis or liver disease in children include:

  • Yellow discoloration of the skin and eyes (easiest to see in natural daylight and on the sclera, the white part of the eye)
  • Dark urine (tea- or cola-colored, indicating bilirubin excretion through the kidneys when the liver pathway is compromised)
  • Pale or clay-colored stools (indicating that bile is not reaching the intestines)
  • Abdominal pain or tenderness, particularly in the right upper quadrant where the liver is located
  • Unexplained fatigue and loss of appetite lasting more than a few days
  • Nausea and vomiting without a clear cause such as gastroenteritis
  • Itching (pruritus), which occurs when bile salts accumulate in the skin
  • Easy bruising or bleeding, which may indicate impaired production of clotting factors by the liver

If your child develops jaundice outside the newborn period, do not wait to see if it resolves on its own. This is a medical situation that requires blood tests — at minimum, a complete blood count, liver function panel (ALT, AST, bilirubin, albumin), and hepatitis serology — to determine the cause and severity.

Keeping a record of when symptoms first appeared, how they have progressed, and any associated factors (recent travel, new medications, sick contacts, dietary changes) can be invaluable during a medical evaluation. WatchMyHealth's symptom logging feature allows you to document these observations with timestamps, creating a timeline that helps clinicians make faster and more accurate diagnostic decisions.

Vaccination: The Single Most Effective Prevention Strategy

Two of the five hepatitis viruses — A and B — are preventable with highly effective vaccines. Together, these two vaccines represent one of the greatest successes in the history of infectious disease prevention. Their impact on children's health globally has been extraordinary, and yet vaccination coverage gaps persist in many regions.

Hepatitis B Vaccination Schedule

The standard WHO-recommended schedule for hepatitis B vaccination is:

  • Birth dose: Within 24 hours of delivery (critical for preventing mother-to-child transmission)
  • Second dose: At 4 weeks of age
  • Third dose: At 6 months of age (sometimes given as part of a combination vaccine at 8 or 16 weeks depending on the national schedule)

For infants born to HBV-positive mothers, the birth dose should be accompanied by hepatitis B immune globulin (HBIG), which provides immediate passive immunity while the vaccine stimulates active immune responses. This combination is approximately 85 to 95 percent effective at preventing chronic HBV infection in the infant.

Hepatitis A Vaccination Schedule

The CDC recommends:

  • First dose: At 12 to 23 months of age
  • Second dose: At least 6 months after the first dose

Children who are not vaccinated by age 2 can receive catch-up vaccination at any age. The vaccine is also recommended for travelers to endemic areas, people with chronic liver disease, and during outbreaks.

Why Both Vaccines Matter

Hepatitis B vaccination prevents not only HBV but also HDV (since HDV cannot exist without HBV). Hepatitis A vaccination prevents an infection that, while usually mild in young children, can cause outbreaks in schools and communities, significant illness in older children and adults, and rare but devastating fulminant liver failure.

A 2022 systematic review in The Lancet Global Health estimated that hepatitis B vaccination had prevented approximately 310 million chronic infections in the birth cohorts born between 1990 and 2020. The authors projected that maintaining and expanding current vaccination programs could prevent 42 million HBV-related deaths by 2100.

Non-Viral Hepatitis in Children: The Other Causes

Viruses are the most common cause of hepatitis in children, but they are not the only cause. Several non-viral conditions can produce liver inflammation that is equally or even more dangerous.

Autoimmune Hepatitis

Autoimmune hepatitis (AIH) occurs when the immune system mistakenly attacks liver cells. It is relatively rare in children — estimated incidence is approximately 0.4 to 2 per 100,000 children per year — but it can be severe and requires long-term immunosuppressive therapy. A 2019 clinical practice guideline from ESPGHAN noted that untreated AIH progresses to cirrhosis in the majority of cases. With treatment (typically prednisolone plus azathioprine), remission can be achieved in approximately 80 percent of children, but relapse rates after treatment withdrawal are high, and many children require indefinite maintenance therapy.

Drug-Induced Liver Injury

Children's livers are vulnerable to damage from medications, herbal supplements, and toxins. Acetaminophen (paracetamol) overdose is the leading cause of acute liver failure in children in high-income countries. Even at therapeutic doses, acetaminophen can cause liver injury in children who are fasting, dehydrated, or receiving certain other medications that induce hepatic enzyme activity.

A 2018 study in Hepatology found that acetaminophen accounted for approximately 40 percent of pediatric acute liver failure cases in the United States. The margin between a therapeutic dose and a toxic dose is narrower than many parents realize, particularly for young children — making accurate weight-based dosing essential. WatchMyHealth's medication tracking feature can help parents log doses and timing, reducing the risk of accidental double-dosing or dosing errors during busy household routines.

Metabolic Liver Diseases

Several inherited metabolic conditions affect the liver in childhood, including Wilson disease (copper accumulation), alpha-1 antitrypsin deficiency (protein misfolding), and various glycogen storage diseases. These conditions are individually rare but collectively represent a significant cause of chronic liver disease in children. Many are treatable if diagnosed early, which reinforces the importance of pursuing a thorough diagnostic workup whenever a child presents with unexplained liver enzyme elevations.

Non-Alcoholic Fatty Liver Disease

Perhaps the most rapidly growing liver condition in children is non-alcoholic fatty liver disease (NAFLD), driven by the global rise in childhood obesity. A 2019 meta-analysis in Pediatrics estimated that NAFLD prevalence among the general pediatric population was approximately 7.6 percent, rising to 34 percent among obese children. NAFLD is often asymptomatic and detected incidentally through elevated liver enzymes on routine blood work. However, a subset of cases — non-alcoholic steatohepatitis (NASH) — involves active liver inflammation and can progress to fibrosis and cirrhosis even in childhood.

The primary treatment for pediatric NAFLD is lifestyle modification: dietary improvements (reducing sugar-sweetened beverages, increasing fruits and vegetables, limiting processed foods) and increased physical activity. There are currently no FDA-approved medications specifically for pediatric NAFLD, though several are in clinical trials.

Protecting Children's Liver Health: Evidence-Based Strategies

Liver health in children is not just about avoiding hepatitis viruses. It involves a combination of vaccination, nutrition, medication safety, and awareness of warning signs.

Vaccinate on Schedule

Ensure your child receives both the hepatitis B series (starting at birth) and the hepatitis A vaccine (starting at 12 months). If your child has fallen behind on vaccinations, catch-up schedules are available — talk to your pediatrician. If you are pregnant and have not been tested for hepatitis B, request testing, as your HBV status directly determines what interventions your newborn needs at birth.

Practice Food and Water Safety

Hepatitis A and E are both transmitted through contaminated food and water. When traveling to countries with limited sanitation infrastructure, drink only bottled or boiled water, avoid raw or undercooked shellfish, and peel fruits yourself. Teach children thorough handwashing with soap — this simple measure is one of the most effective barriers to fecal-oral transmission of any pathogen.

Use Medications Carefully

Always use weight-based dosing for acetaminophen and ibuprofen in children. Use the measuring device that comes with the medication, not a household spoon. Never give multiple products containing acetaminophen simultaneously (many cold and flu preparations contain it as a hidden ingredient). Store all medications out of children's reach.

Maintain a Healthy Weight

With NAFLD emerging as a significant pediatric liver condition, maintaining a healthy weight through balanced nutrition and regular physical activity is increasingly important for liver health. Limit sugar-sweetened beverages, encourage water as the default drink, and aim for at least 60 minutes of moderate-to-vigorous physical activity per day — the baseline recommendation from both the WHO and the American Academy of Pediatrics.

Know Your Family History

If there is a family history of liver disease, Wilson disease, alpha-1 antitrypsin deficiency, or other metabolic conditions, inform your child's pediatrician. Early screening for these conditions can lead to interventions that prevent or delay serious liver damage.

Monitor and Document

Children with known liver conditions, those on medications that affect the liver, or those recovering from hepatitis benefit from consistent monitoring. Tracking symptoms, medication doses, dietary patterns, and energy levels over time creates a dataset that helps physicians make more informed decisions about care. WatchMyHealth's health journal provides a structured way to log these observations day by day, building a longitudinal record that is far more useful than trying to recall details during a clinic visit weeks later.

What the 2022 Outbreak Taught Us

The mystery hepatitis cluster of 2022 was not just a medical puzzle. It was a reminder of several broader truths about children's health.

First, viruses interact with each other in ways we do not fully understand. The emerging evidence that AAV2 — a virus most virologists considered harmless — could contribute to severe liver disease when combined with a common adenovirus in susceptible children was genuinely surprising. It challenges the simplistic notion that a single pathogen equals a single disease.

Second, immune development depends on exposure. The immunity gap hypothesis — that children who missed normal early-childhood viral exposures during pandemic lockdowns had atypically strong immune reactions when they finally encountered these viruses — has implications beyond hepatitis. It suggests that the immune calibration that occurs in the first years of life is not just beneficial but necessary, and that prolonged absence of common childhood infections may carry its own risks.

Third, surveillance systems work. The 2022 outbreak was detected relatively quickly because clinicians in Scotland recognized an unusual pattern and reported it. The international response, while imperfect, coordinated investigations across dozens of countries within weeks. The molecular detective work that identified AAV2 as a potential cofactor was published within a year. In the context of rare pediatric conditions, this is remarkable speed.

Fourth, vaccination matters even for conditions it does not directly prevent. While the 2022 mystery hepatitis was not caused by hepatitis A or B, the diagnostic process for every affected child began by ruling out vaccine-preventable causes. Children who were fully vaccinated could be quickly identified as cases of the novel syndrome, accelerating the investigation. In any outbreak scenario, a well-vaccinated population simplifies the diagnostic landscape and allows resources to be focused on the unknown.

When to Seek Medical Attention

Most childhood illnesses that cause vomiting, fatigue, or mild abdominal pain resolve on their own within a few days. But certain combinations of symptoms warrant prompt medical evaluation because they may indicate liver involvement:

  • Jaundice (yellow skin or eyes) in any child beyond the newborn period
  • Dark urine combined with pale stools — this combination specifically suggests a biliary or hepatic problem
  • Right upper abdominal pain that is persistent or worsening
  • Prolonged vomiting (more than 24 to 48 hours) with increasing lethargy
  • Unexplained bruising or bleeding (nosebleeds, bleeding gums, bruises without clear trauma)
  • Persistent itching without a visible skin rash
  • Abdominal swelling (ascites), which may indicate advanced liver disease
  • Confusion or behavioral changes in a child who is also jaundiced (this can indicate hepatic encephalopathy and is a medical emergency)

If you observe any of these warning signs, do not adopt a wait-and-see approach. Early intervention in hepatitis and other liver conditions consistently leads to better outcomes. A simple blood draw measuring liver enzymes (ALT and AST), bilirubin, and a coagulation panel can provide critical diagnostic information within hours.

The Bottom Line

Hepatitis in children is not a single disease but a spectrum of conditions with different causes, different severity levels, and different prevention strategies. Two of the most important forms — hepatitis A and B — are preventable with safe, highly effective vaccines that should be part of every child's immunization schedule. The 2022 mystery outbreak, while alarming, appears to have been a transient consequence of unusual pandemic-era conditions rather than the emergence of a new permanent threat.

The most important things parents can do are straightforward: vaccinate on schedule, practice good hygiene and food safety, use medications carefully and at correct doses, maintain awareness of jaundice and other liver warning signs, and seek prompt medical attention when those signs appear. The liver is a remarkably resilient organ — but in children, whose livers are still developing, early recognition of problems makes the difference between full recovery and lasting damage.